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ABSTRACT
Progressive supranuclear palsy (PSP) is a distinctive form of neurodegenerative 
disease which affects the brainstem and basal ganglia. Patients present supranuclear 
ophthalmoplegia, postural instability and mild dementia. PSP is defined neuropathologically 
by the accumulation of neurofibrillary tangles in the subthalamic nucleus, pallidum, red 
nucleus, substantia nigra, striatum, pontine tegmentum, oculomotor nucleus, medulla and 
dentate nucleus. Over the last decade many lines of investigations have helped refine PSP 
in many aspects and it is the purpose of this review to help neurologists identify PSP, to 
better understand its pathophysiology and to provide a more focused, symptom-based 
treatment approach. 
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Paralisia supranuclear progressiva: conceitos atuais
RESUMO
A paralisia supranuclear progressiva (PSP) é uma doença neurodegenerativa, que afeta 
principalmente o tronco cerebral e os núcleos da base. O quadro clínico se caracteriza 
por oftalmoparesia supranuclear, instabilidade postural e demência . Do ponto de vista 
anátomo-patológico, a PSP se caracteriza por acúmulo de emaranhados neurofibrilares no 
núcleo subtalâmico, globo pálido, núcleo rubro, substância negra, estriado, tegumento da 
ponte, núcleos oculomotores, bulbo e núcleo denteado. Nas últimas décadas, muitas linhas 
de pesquisa têm colaborado para redefinir a PSP em muitos aspectos. Os objetivos dessa 
revisão são auxiliar o neurologista geral na identificação da doença, compreensão da sua 
fisiopatologia, além de apresentar alternativas para seu tratamento sintomático. 
Palavras-chave: paralisia supranuclear progressiva, parkinsonismo atípico, taupatias.
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Progressive supranuclear palsy (PSP), 
also called Steele-Richardson-Olszews-
ki syndrome, is a distinctive and probably 
under diagnosed neurodegenerative syn-
drome. It is the most common cause of de-
generative parkinsonism after Parkinson’s 
disease (PD) in most series1,2. The “classic” 
PSP syndrome is characterized by gait dis-
order, ophthalmoparesis (down gaze palsy), 
cognitive dysfunction and parkinsonism, 
but a number of PSP phenotypic variants 
have been described recently1,2. The prev-
alence of PSP is age-dependent and esti-
mated at 6% to 10% that of PD, or 6-7 cas-
es per 100.000. The disease has a peak on-
set at age 63 and no reported cases before 
the age of 40. The correct diagnosis is usu-
ally made 3.6 to 4.9 years after the onset of 
clinical signs2.
In the last few years, we have learned 
much about clinical, neuroimaging, mo-
lecular pathology and genetic of PSP. This 
syndrome is a tauopathy, with deposits of 
neurofibrillay tangles in the brain, which 
are mainly composed of hyperphosphory-
lated microtubule-associated protein tau. 
Tauopathies refers generally to neurode-
generative disorders with prominent tau 
pathology in the neuronal or glial cells. Tau 
is a microtubule-associated protein ex-
pressed in neurons, which in tauopathies 
forms abnormal, fibrillar structures of ag-
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gregated, hyperphosphorylated and ubiquinated tau3,4. 
There are an increasing number of tauopathies described, 
including Alzheimer’s disease, corticobasal degeneration, 
postencephalitic parkinsonism, Parkinson-dementia com-
plex of Guam, Guadeloupian parkinsonism, frontotempo-
ral dementia with parkinsonism linked to chromosome 
17, Pick disease and Niemann-Pick disease type C2-4.
PSP is pathologically defined by the accumulation of 
tau protein and neuropil threads in the subthalamic nu-
cleus, pallidum, red nucleus, substantia nigra, striatum, 
pontine tegmentum, oculomotor nucleus, medulla and 
dentate nucleus. Similar histopathological findings can 
be seen in other forms of tauopathies (ex. Guadeloupian 
parkinsonism), complicating the pathological diagnosis of 
PSP. The most specific features are star-shaped astrocyt-
ic tufts and neurofibrillary tangles that can be seen with 
light microscopy and that immunostain strongly with an-
tibodies to tau3,4.
In adult human brain tau has six alternatively spliced 
isoforms that are derived from a single gene. Disordered 
regulation of exon 10 splicing may therefore explain tau 
aggregation into neurofibrillary tangles in PSP and oth-
er tauopathies.The microtubule-binding domain contains 
either three 31 amino acids repeats (3R) or four 31 amino 
acids repeats (4R) and in normal adults brains the propor-
tion of 3R and 4R tau are similar. In PSP the ratio of hu-
man brain tau isoforms is at least 3:1 in favor of 4R tau4. 
PSP has traditionally been considered a sporadic dis-
ease, but its consistent genetic association with markers 
in chromosome 17q21 and reports of familial PSP cas-
es suggest a familial aggregation. A linkage study on a 
large Spanish family with typical autosomal dominant 
PSP mapped a candidate gene in a 3.4-cM region in chro-
mosome 1q31.1. Several families with PSP-like presenta-
tion have been described. MAPT (microtubule-associat-
ed protein tau) and PARK-2 mutations may cause a PSP-
like phenotype. Mutations in the LRRK2 gene cause an 
autosomal dominant parkinsonism and may present as a 
PSP-like parkinsonism. Rajput and coworkers described 
a family, with parkinsonism and LRRK2 (G2019S muta-
tion), where the affected proband had tau-immunopos-
itive neurofibrillary tangles at autopsy rather than Lewy 
body disease5. Santos-Rebouças and colleagues reported 
the co-occurrence of sporadic parkinsonism and late-on-
set Alzheimer’s disease in a Brazilian male with mutations 
in the LRRK2 gene6. The MAPT H1 haplotype is probably 
a genetic risk locus for PSP, but the haplotype H2 plays a 
protective role7-9.
Clinical subtypes
PSP is frequently misdiagnosed, most commonly as 
PD, and less than a half of patients with pathologically-
proven PSP will have received the diagnosis of PSP at pre-
sentation. The National Institute of Neurological Disor-
ders and Stroke/ Society for PSP (NINDS/SPSP) crite-
ria detect only 50-70% of patients within 3 years of dis-
ease onset2. Several clinical variants have recently been 
identified and a new nosology is emerging. These clinic-
pathological variants can be separated by differences in 
their severity, regions of pathology involvement and clin-
ical features.
Richardson’s syndrome (RS): Starting after the age 
40, this is the “classical” and more common picture of PSP. 
A lurching gait and unexplained fall backwards without 
loss of consciousness are the commonest presentations 
of PSP. Patients have more axial than appendicular rigid-
ity and retrocollis is a common form of dystonia (Fig 1). 
Early ocular symptoms include blurred vision, slow sac-
cades, photophobia, slowing of vertical saccades and in-
voluntary eyelid closure due to blepharospasm. Vertical 
supranuclear gaze palsy is the definitive diagnostic feature 
but this commonly develops many years after disease on-
set. In RS, apathy, intellectual slowing and impairment of 
executive functions are also consistent findings, and may 
include the “applause sign”, a test of impaired motor con-
trol leading to perseveration due to frontal dysfunction. 
Apraxia of eyelid opening, a slow and slurred speech and 
difficulties in swallowing are other typical features. Limb-
kinetic apraxia, or difficulty performing simple gesture 
and the fine movements, although most often associat-
ed with corticobasal syndrome, also occurs in PSP. Most 
patients become dependent on others for care within 3 
to 4 years of diagnosis and the common causes of death 
are aspiration pneumonia, primary neurogenic respira-
tory failure and pulmonary emboli. RS consists of diffuse 
tau pathology and the most severely affected regions are 
subthalamic nucleus and substantia nigra3,4,7,10.
PSP-parkinsonism (PSP-P): The PSP-P phenotype 
Fig 1. An illustrative image of a patient with progressive supranu-
clear palsy with 5 years of disease duration and retrocollis. Note 
that the patient is already in wheelchairs. 
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comprises about one-third of the cases and is a more in-
dolent form with a PD-like presentation. The features in-
clude bradykinesia and rigidity, tremor, asymmetric onset, 
normal eye movements and a clear, but transient levodo-
pa response. Parkinsonism dominates the early clinical 
picture and a jerky postural tremor and even a 4-6 HZ 
rest tremor are common in PSP-P patients. Falls and cog-
nitive impairment occur later in PSP-P than in RS. These 
syndromes can be distinguished by their clinical pictures 
in the first 2 years but there is a clinical overlap, and after 
6 years of follow up, the clinical phenomenology might 
become similar. The patients with PSP-P have less severe 
tau pathology than those with RS3,7,10.
PSP-pure akinesia with gait freezing (PSP-PAGF): 
This PSP-phenotype is highly predictive of PSP-tau pa-
thology. The clinical picture is a syndrome with progres-
sive gait disturbance with start hesitation and subsequent 
freezing of gait, speech or writing, without tremor, rigid-
ity, dementia or eye movement abnormality during the 
first 5 years of the disease. The classical PSP features may 
be delayed or even absent. The isolated gait freezing may 
also appear in several other diseases including subcortical 
white matter ischemia, PD and dementia with Lewy bod-
ies. The tau-pathology in these individuals is described 
as pallido-nigro-luysial. The restricted distribution of pa-
thology in PAGF is thought to be the cause of clinical dif-
ferences and better prognosis3,10.
PSP-progressive non-fluent aphasia (PSP-PNFA): 
The clinical presentation is consistent with non-fluent spon-
taneous speech, hesitancy, phonemic errors and agramma-
tism. The neuropsychological profile in these cases is sim-
ilar to other patients with PNFA. However, patients with 
PSP-PNFA have more marked reduction in propositional 
speech, fewer speech errors and less marked impairment 
of literacy skills. Moreover, there are more severe associat-
ed deficits of episodic memory and praxis. These PSP-PN-
FA cases have less prominent midbrain atrophy but more 
marked prefrontal atrophy. PNFA fits within the spectrum 
of frontotemporal dementia but in a small case series pa-
tients with PNFA had underlying PSP-tau pathology 10,11.
PSP-cerebellar: Kanazawa and coworkers recently 
described the cerebellar involvement in PSP. They ana-
lyzed 22 consecutive Japanese patients with pathologically 
proven PSP and 3 patients developed cerebellar ataxia as 
the initial and main symptom. All the patients with cere-
bellar ataxia exhibited more neuronal loss with gliosis and 
higher densities of coiled bodies in the cerebellar dentate 
nucleus than those without cerebellar ataxia12.
PSP-corticobasal syndrome (PSP-CBS): Is char-
acterized by progressive, asymmetric dyspraxia, cortical 
sensory loss, including an alien limb, jerky dystonia of 
the limb and bradykinesia that is unresponsive to levodo-
pa. Several studies showed that only 50% of patients with 
CBS have pathology that is typical of corticobasal degen-
eration and the PSP-CBS seems to be a rare presentation 
of PSP-tau pathology. For instance, in neuropathologically 
studied cases, a “corticobasal syndrome” was observed in 
PSP, Pick disease, Alzheimer’s disease, frontotemporal de-
mentia with parkinsonism and frontotemporal lobar de-
generation with ubiquitin-positive inclusions 3,7,10. 
Clinical criteria for the diagnosis of PSP
There are many proposed clinical criteria for PSP and 
the majority of them have a similar characteristic: high 
specificity and low sensitivity. Although the classic PSP 
syndrome presents with clear clinical signs in later stag-
es, the clinical variants recently described are less dis-
tinctive, and many patients with PSP are initially thought 
to have PD, multiple system atrophy, Lewy body disease 
and other sporadic primary tauopathies. Maybe this fact 
explains the high specificity and low sensibility of clini-
cal criteria for PSP10.
The NINDS/SPSP clinical diagnostic criterion (Table 
1) was compiled to reliably identify patients for clinical 
research who had underlying PSP-tau pathology13. This 
specific criteria state that early falls due to postural in-
stability and supranuclear gaze palsy or slowed vertical 
saccades are the most helpful defining clinical features. 
When these two physical signs are present, it is extreme-
ly useful in differentiating between PSP and PD. In spite 
of this, the absence of falls and gaze palsies in many pa-
tients do not exclude the diagnosis of PSP10.
In accord to some studies, the application of current 
available operational criteria, including those proposed 
by the NINDS/SPSP, fails to improve the accuracy of fi-
nal diagnosis by neurologists. Although supranuclear gaze 
palsy, prominent early postural instability with falls, and 
frontal behavioral or cognitive deficits are the cardinal 
features of PSP, all may occur in other neurodegenerative 
disorders, potentially leading to some false-positive diag-
noses. Early differentiation between PSP and other neuro-
degenerative movement disorder syndromes or demen-
tias can be important for a number of reasons, including 
foreseeing differences in the natural course, choosing ap-
propriate pharmacologic approaches, and avoiding inclu-
sion of misdiagnosed patients in treatment trials14-16.
Biomarkers for the diagnosis of PSP
One of the key issues in the management of neurode-
generative disorders is the requirement for reliable bio-
markers to increase diagnostic accuracy. In the last few 
years, several biologic markers have been tested, but no 
specific biologic tool for early PSP detection is available. 
Actually, all the proposed biomarkers showed an individ-
ually considerable overlap between PSP and other neuro-
degenerative disorders. Several studies aimed at evaluat-
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ing tau levels in cerebral spinal fluid (CSF) in PSP com-
pared with patients affected by either other tau-related 
disorders or other neurodegenerative extrapyramidal syn-
dromes, such as synucleinopathies14,17. In CSF, extended 
(55 kDa) and truncated (33 kDa) tau forms have been pre-
viously recognized, and the tau 33 kDa/55 kDa ratio has 
been found significantly reduced in PSP in comparison 
with other neurodegenerative disorders14. 
Moreover, recent data have shown that tau protein 
burden, type and ultrastructure in CSF and in patholog-
ical analyses are different between the various subtypes 
of PSP described above, contributing not only to separate 
the PSP phenotypes clinically, but also affecting the sever-
ity and distribution of the histopathologycal lesions17.
Brain imaging
As aforementioned, the diagnosis of PSP relies mainly 
on clinical data, and misdiagnosis can be frequent, espe-
cially in the early disease stages18. According to a recent 
study it is estimated that at least 1 in every 20 patients 
taking medication for PD is misdiagnosed19, and these 
data may be even worse taking into account PSP, which is 
much less frequent than PD, and under diagnosed.
Nevertheless, conventional structural and function-
al brain imaging may help not only in the differential di-
agnosis of PSP between PD and other atypical forms of 
parkinsonism [multiple system atrophy (MSA) and CBD], 
but also aid to understand the neurobiological basis of 
this neurodegenerative disorder20.
Table. NINDS-SPSP clinical criteria for the diagnosis of PSP.
PSP Mandatory inclusion criteria Mandatory exclusion criteria Supportive criteria
Possible Gradually progressive disorder
Onset at age 40 or later
Either vertical (upward or down-
ward gaze) supranuclear palsy or 
both slowing of vertical saccades 
and prominent postural instabili-
ty with falls in the first year of dis-
ease onset
No evidence of other diseases that 
could explain the foregoing fea-
tures, as indicated by mandatory 
exclusion criteria
Recent history of encephalitis
Alien limb syndrome, cortical sen-
sory deficits, focal frontal or tem-
poroparietal atrophy
Hallucinations or delusions unrelat-
ed to dopaminergic therapy
Cortical dementia of Alzheimer’s 
type (severe amnesia and aphasia 
or agnosia, according to NINCDS-
ADRA criteria)
Prominent, early cerebellar symp-
toms or prominent, early unex-
plained dysautonomia (marked hy-
potension and urinary disturbances)
Symmetric akinesia or rigidity, 
proximal more than distal
Abnormal neck posture, espe-
cially retrocollis
Poor or absent response of par-
kinsonism to levodopa therapy
Early dysphagia and dysarthria
Early onset cognitive impairment 
including at least two of the fol-
lowing: apathy, impairment in 
abstract thought, decreased ver-
bal fluency, utilization or imita-
tion behavior, or frontal release 
signs
Probable Gradually progressive disorder
Onset at age 40 or later
Vertical (upward or downward gaze) 
supranuclear palsy and prominent 
postural instability with falls in the 
first year of disease onset
No evidence of other diseases that 
could explain the foregoing fea-
tures, as indicated by mandatory 
exclusion criteria
Severe, asymmetric parkinsonian 
signs (i.e., bradykinesia)
Neuroradiologic evidence of rele-
vant structural abnormally (i.e. bas-
al ganglia or brainstem infarcts, lo-
bar atrophy)
Whipple’s disease, confirmed by 
polymerase chain reaction, if indi-
cated
Definite Clinically probable or possible PSP 
and histopathology evidence of 
typical PSP
 
PSP: Progressive Supra Nuclear Palsy; NINDS-SPSP: National Institute of Neurological Disorders and Stroke Society for Progressive Supra Nuclear Palsy; NINCDS-
ADRA: National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer’s Disease and Related Disorders Association.
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Conventional structural brain MRI
Conventional structural brain MRI can help on the 
differentiation between PSP and PD, and other atypical 
parkinsonian subtypes. Using an automated computer dif-
ferential classification in parkinsonian syndromes via pat-
tern analysis on MRI, Dushesne and coworkers obtained 
91% accuracy (agreement with long-term clinical follow-
up), 88% specificity, and 93% sensitivity in the diagnosis of 
PSP21. In the paper by Cosottini and coworkers, assessing 
midbrain atrophy through morphometric measurements 
in patients with clinically diagnosed PSP they found that 
the midbrain area had the highest diagnostic accuracy in 
distinguishing between PSP and other conditions, with a 
sensitivity of 100% and specificity of 90.5%22. 
The following brain MRI regions should be carefully 
analyzed in the evaluation of patients with suspected PSP, 
and further details on the measurement procedures can 
be found elsewhere23: [1] Presence or not of enlargement 
of the third ventricle; [2] Anteroposterior diameter of the 
midbrain; [3] Quadrigeminal plate thickness; [4] Interpe-
duncular angles; [5] Brainstem volumetry; [6] Volumetry 
of the caudate nucleus and putamen; [7] Presence or not 
of hypersignal in the periaqueductal region.
We make available illustrative brain MRI images of a 
patient with PSP (Fig 2). 
Functional neuroimaging
Functional neuroimaging provides a unique in vivo 
opportunity to study the neurobiological abnormalities 
that takes place in neurodegenerative disorders assess-
ing cerebral blood flow, patterns of regional glucose me-
tabolism and dopaminergic binding sites. The rationale of 
functional neuroimaging consists of the radioligand with 
high affinity to a particular binding site. Further details on 
this methodology can also be found elsewhere24.
Regional cerebral blood flow (rCBF)
SPECT imaging techniques using the technetium-
based radioligand ECD showed hypoperfusion of the an-
terior cingulate and medial frontal cortex in PSP patients 
as compared to controls and PD. In PSP patients the rCBF 
impairment extended to the pre-supplementary motor 
area and prefrontal cortex, areas involved in executive 
function and motor networks. Compared with PSP pa-
tients, PD patients showed a mild rCBF decrease in asso-
ciative visual areas which could be related to the known 
impairment of visuospatial function. Therefore, the ante-
rior cingulate hypoperfusion seems to be an early, distinct 
brain abnormality in PSP as compared with PD25.
Glucose metabolism 
Using PET with [18F]-FDG, a characteristic feature 
among the PSP group is brain glucose hypometabolism 
along the midline of the frontal regions and in the brain-
stem, notably midbrain. Decreased metabolism was also 
noted in the superior frontal and insular areas, and in the 
caudate nucleus26. Interestingly, these abnormalities seen 
in PSP also occur, but to a lesser extent, in PSP-PAGF, 
suggesting that both diseases are actually part o the same 
spectrum27. 
Molecular imaging (dopaminergic binding sites)
Dopaminergic binding sites can be evaluated using 
SPECT and PET radiotracers that selectively bind to pre 
and postsynaptic targets. Pre-synaptic binding sites that 
are studied in degenerative parkinsonisms consist of 
the dopamine transporter (DAT; SPECT [99mTc]-TRO-
DAT-1, [123I]-β-CIT, [123I]-FP-CIT or PET [11C]-MP), ve-
sicular monoamine transporter (VMAT2; PET [11C]-DT-
BZ), and dopa-decarboxylase activity (PET [18F]-FDOPA). 
Overall, they point toward the integrity of pre-synaptic 
Fig 2. Brain MRI illustrative images of a patient with progressive supranuclear palsy [A] Enlargement of the third ventricle (coronal plan; 
T2-weighted); [B] Internal-1 and external-2 interpeduncular angles showing midbrain atrophy (axial plan; T1-weighted); [C] Quadrigemi-
nal thickness showing atrophy (sagittal plan; T1-weighted); [D] Periaqueductal hypersignal (sagittal plan; FLAIR).
Arq Neuropsiquiatr 2010;68(6)
 943
Progressive supranuclear palsy: new concepts
Barsottini et al.
dopaminergic terminals. On the other hand, we can also 
study post-synaptic receptors (D2 receptors) using spe-
cific radioligands either for SPECT ([123I]-IBZM or IBF) 
or PET ([11C]-Raclopride)24. 
In general, the posterior putamen is useful in differ-
entiating parkinsonism from controls but is not helpful 
in further discriminating between PD, multiple system 
atrophy, and PSP. However, D2 receptors may help fur-
ther differentiate between parkinsonian disorders, since 
drug-naïve PD and PSP patients have normal D2 receptor 
availability, while MSA patients show reduced D2 recep-
tor availability. Therefore, posterior putamen D2 binding 
above the normal range of healthy controls in a parkin-
sonian patient before dopaminergic treatment suggests a 
diagnosis of PD or PSP, whereas a result below the normal 
range suggests an alternative diagnosis, such as MSA28. 
In PD a distinctive neurodegenerative pattern of do-
pamine cell loss can be assessed using in vivo molecular 
imaging, with more pronounced involvement of the pos-
terior part of the putamen contralateral to the most affect-
ed side, and lesser involvement of the caudate ipsilateral 
to the most affected limb24. On the contrary, in PSP DAT 
imaging (putamen-to-caudate ratio) suggests a more uni-
form involvement of dopamine nerve terminals in both 
caudate nucleus and putamen29. In Fig 3 we highlight an 
illustrative brain SPECT imaging using TRODAT-1 as the 
radiopharmaceutical in a PSP-P subject matched for age 
and gender to a healthy control subject. 
Treatment of PSP
The “multisystem” pathology of this degenerative dis-
ease, as mentioned above, predicts the challenge of treat-
ment7. The scope of this section is reviewing pharmaco-
logical therapies, future disease modifying strategies, sur-
gical implants and palliative methods. 
Symptomatic treatment 
Although parkinsonism is a characteristic feature in 
PSP, it is often distinct from that typically seen in PD, not 
only in clinical picture, but also in levodopa (LD) respon-
siveness. This is explained by the pathology distribution 
of PSP, involving subthalamic nucleus, pallidum, substan-
tia nigra, striatum, and other regions in brainstem3,4.
Poor or absent response to LD has been considered 
one of the diagnostic criteria for PSP, while marked or 
prolonged LD benefit has been included as an exclusion 
criteria30. Most studies shows that LD benefit, if exists, is 
minimal and transient. A review of the literature identi-
fied an approximate response rate of 26 percent31, and the 
average dosage administrated on different trials is around 
500 mg-1 g/day of LD with a dopa decarboxylase inhibitor. 
Responsiveness to LD is probable different between 
subtypes of PSP, being poor in classical RS, and initial-
ly moderate in PSP-P32. Considering side effects, LD-in-
duced dyskinesias seems to be rare, however, some can 
develop worsening of motor features and dystonia33. A 
retrospective study involving 12 autopsy-confirmed cas-
es of PSP, found a positive response in four of 11 patients 
using LD, and in two of 6 using dopamine agonist. LD-
induced dyskinesia was present in only one LD respon-
sive patient34. 
The absence of benefit with pramipexole therapy has 
been showed in a study involving six patients, in which 
none responded significantly, and three presented ad-
verse effects as hallucinations and worsening of motor 
symptoms35. 
Fig 3. An illustrative brain SPECT imaging (axial plane) using a dopamine transporter li-
gand (TRODAT-1) of a 65-year-old male healthy subject [A] matched with a 61-year-old 
male patient with progressive supranuclear palsy with 5 years of disease duration [B]. The 
Figure shows a marked decreased uptake of the radioligand in both caudate and puta-
men (arrows) as compared to the control.
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Drugs directed to systems other than dopaminergic, 
such as serotonergic, noradrenergic, and cholinergic, were 
also tried in PSP. Serotoninergic drugs, such as selective 
serotonin reuptake inhibitors, 5-hydroxytryptophan, and 
methysergide have no confirmed benefit in PSP31,33, nei-
ther have cholinergic drugs, such as AChE inhibitors, 
and muscarinic agonists36. Concerning cognitive deficit 
in PSP, rivastigmine lead to a slight improvement in spe-
cific function in a small series with five cases37. Concern-
ing noradrenergic drugs, idazoxan, a α-2 antagonist was 
found to improve four of seven patients, however efar-
oxan, a more potent α-2 antagonist did not lead any im-
provement of symptoms in a placebo controlled trial38,39. 
Tricyclic antidepressants improved gait and rigidity 
in three of four patients in a small double-blind trial40, on 
the other hand, these drugs have a high risk/benefit ratio 
in population with PSP, according to a published review41. 
In spite of this, nortryptiline seems to be useful as an op-
tion for depression in this population, but it lacks ran-
domized controlled data that support this observation42.
Following the hypothesis that GABA (gamma amino 
butyric acid) is involved in the pathogenesis of PSP, due 
to loss of interneurons containing benzodiazepine/GABA 
receptors, zolpidem, a GABA agonist of the benzodiaz-
epine subtype receptor BZ1, was administered to isolated 
cases and small groups of patients with PSP. These works 
showed a motor benefit, including in eye movements dur-
ing therapy. Further studies with this drug are necessary, 
to elucidate if this benefit is transient or sustained, as the 
ones already done found different outcomes43,44. Anoth-
er GABAergic drug, gabapentin has failed in ameliorat-
ing parkinsonism in PSP, however it caused some effect 
in oculomotor reflex45.
As presented here, until this time, there is no evidence 
enough to recommend a specific symptomatic treatment 
in PSP. In practice, physicians prescribe symptomatic 
drugs empirically and individualized in each patient. 
Botulinum toxin 
According to our previous published experience the 
overall frequency of dystonia in Brazilian patients with 
atypical parkinsonian syndromes is of 50%46. Therefore, 
botulinum toxin may be helpful in PSP for treating dysto-
nia, such as retrocollis (Fig 1), and apraxia of eyelid open-
ing, reducing disability provoked by these symptoms36. 
This must be used with cautions to avoid worsening of 
dysphagia. 
Disease modifying therapies
The Neuroprotection and Natural History in Parkin-
son Plus Syndromes (NNIPPS) study randomized PSP 
and MSA patients for receiving riluzole, evaluating sur-
vival as primary outcome. This drug did not have a sig-
nificant effect on survival neither in the rate of function-
al deterioration47.
Development of future therapies will come from 
a greater understanding of PSP and other tauopathies 
pathophysiology. Glycogen synthase kinase 3 (GSK-3) 
may play a role in tau diseases because it can phos-
phorylate tau in vivo, and inhibition of this enzyme in 
transgenic mice and in drosophila leads to functional 
improvement48,49. Lithium seems to be a GSK-3 inhibitor 
in mice with increased activity of this enzyme, prevent-
ing neuropathologic changes50. 
Several studies point toward: manipulation of splicing 
regulation by RNA stem-loops reducing 4-repeat tau pro-
duction; inhibition of tissue transglutaminase (TGase), an 
enzyme that cross-links substrate proteins into insoluble 
form potentially initiating neurofibrillary tangles forma-
tion; and use of trophic factors36, in order to find a dis-
ease modify therapy.
Surgical treatment 
As deep brain stimulation (DBS) surgery for PD re-
quires response to LD most patients with PSP do not ful-
fill this criterion. A published case that was initially di-
agnosed as PD responsive to LD, but later developed 
atypical signs compatible with PSP-P, presented benefit 
with subthalamic nucleus DBS in ameliorating parkin-
sonism51.
Palliative methods
There are no evidence-based data for palliative treat-
ment in PSP, however these recommendations are based 
on good practice and clinical experience. A multidisci-
plinary team is essential in management of PSP36. Phys-
iotherapist, speech, language, and occupational thera-
pists, and dietitians should be involved in management 
of treatment.
According to development of symptoms, different pal-
liative methods should be recommended. Physicians must 
be aware to predict complications before their occur-
rence. To prevent falls, when postural instability is pres-
ent, weighted walkers and physiotherapist may be neces-
sary. For patients with dysphagia, thickeners, speech ther-
apist and/or percutaneous endoscopic gastrostomy will 
be useful to avoid nutrition deterioration and aspiration 
pneumonia. To ocular phenomena such as decreased rate 
of blinking, vertical palsy and apraxia of eyelid opening, it 
can be used artificial tears, prism glasses and botulinum 
toxin can be used. In the case of excessive drooling, top-
ical or systemic anticholinergic drugs may be used with 
caution, or either botulinum toxin52. 
CONCLUSIONS
Recently, an emerging knowledge in PSP physiopa-
Arq Neuropsiquiatr 2010;68(6)
 945
Progressive supranuclear palsy: new concepts
Barsottini et al.
thology, diagnosis and treatment has become available to 
physicians, but despite all these information PSP still re-
main an under diagnosed disorder. Therefore, we should 
always be careful in the evaluation of patients with par-
kinsonian disorders and keep in mind the most impor-
tant “red flags” that may point out to PSP or other atypi-
cal forms of parkinsonism. These main “red flags” that we 
should take into consideration in clinical practice are: su-
pranuclear gaze palsy, early falls, and unresponsiveness to 
LD. We should also notice that different PSP-phenotypes 
other than the “classic” and PSP-P may lead to misdiag-
nosis, and recently we have also been challenged with a 
PSP-cerebellar phenotype, adding more difficulty to PSP 
diagnosis.
Conventional structural MRI is very helpful, improv-
ing diagnosis accuracy, and some particular areas espe-
cially of the cerebellum-brain stem region should be thor-
oughly assessed. Caution, however, should be considered 
in patients with recent disease onset since these charac-
teristic brain MRI alterations may not be evident. 
Functional neuroimaging may also help, but yet its 
main role is much more in elucidating in vivo PSP-phys-
iopathology, for instance, demonstrating regional cere-
bral glucose hypometabolism in the midline region of 
the frontal lobe and brainstem, particularly midbrain. Of 
note, molecular imaging target to dopaminergic binding 
sites demonstrate a more extensive dopamine cell loss 
than in PD. Finally, promising new therapies are emerg-
ing to at least improve survival rates in PSP, but we are 
still far from a more effective treatment strategy. There-
fore, symptomatic therapy and palliative support is advo-
cated. In the meanwhile, we take the opportunity to rein-
force PSP diagnosis, which is the first step for future, ev-
idence-based, disease-modifying therapies.
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